PB 5 of 2025

National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (February Update) Instrument 2025

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 100(2) of the National Health Act 1953.

Dated 30th January 2025

REBECCA RICHARDSON

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Amendments

National Health (Highly Specialised Drugs Program) Special Arrangement 2021
(PB 27 of 2021) 2

1.       Name

1.            This instrument is the National Health (Highly Specialised Drugs Program) Special Arrangement Amendment (February Update) Instrument 2025.
2.            This instrument may also be cited as PB 5 of 2025.

1.       Commencement

1.            Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1.            Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1.       Authority

 This instrument is made under subsection 100(2) of the National Health Act 1953.

1.       Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)

1.                    Schedule 1, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre‑filled syringe

omit:

1.                    Schedule 1, entry for Maraviroc in each of the forms: Tablet 150 mg; and Tablet 300 mg

insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:

1.                    Schedule 1, entry for Tenofovir in the form Tablet containing tenofovir disoproxil maleate 300 mg
   1.            omit:

1.            omit: